Amneal Pharmaceuticals is trading at $11.83, down 39.33% in after-hours trading, in a move that appears consistent with profit-taking after the recent FDA approval and immediate launch of generic lanreotide. - It closed September 22, 2026, at $19.50, after gaining 7.75% on September 21. - The FDA approval was announced September 18 and carried Competitive Generic Therapy designation. - No new negative announcement, earnings release, or analyst downgrade was identified.